ResearcherVA Greater Los Angeles Healthcare SystemNo recent work listed
Matthew M. Rochefort
Matched on ORCID iD 0009-0001-1046-4701; OpenAlex author ID A5005715175. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers
Papers 8
- Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. Co-author DOI 10.1016/j.jmoldx.2016.03.006↗
- Long-term survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2015.12.024↗
- Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Co-author DOI 10.1038/bjc.2016.121↗
- Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. Co-author DOI 10.1002/jso.24011↗
- Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. Co-author DOI 10.1001/jamasurg.2013.2690↗
- A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. Co-author DOI 10.1007/s11307-014-0733-4↗
- An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. Co-author DOI 10.1016/j.jss.2013.05.095↗
- Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Co-author DOI 10.1245/s10434-013-3159-3↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- James S. Tomlinson · 6 shared papers, 2013–2016 · strength 0.28
- Paper Long-term survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2015.12.024↗
- Paper Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. DOI 10.1016/j.jmoldx.2016.03.006↗
- Paper Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with no… DOI 10.1002/jso.24011↗
- Timothy R. Donahue · 5 shared papers, 2013–2016 · strength 0.22
- Paper Long-term survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2015.12.024↗
- Paper Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with no… DOI 10.1002/jso.24011↗
- Paper Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. DOI 10.1038/bjc.2016.121↗
- Howard A. Reber · 5 shared papers, 2013–2016 · strength 0.22
- Paper Long-term survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2015.12.024↗
- Paper Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with no… DOI 10.1002/jso.24011↗
- Paper Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. DOI 10.1038/bjc.2016.121↗
- Oscar Joe Hines · 5 shared papers, 2013–2016 · strength 0.22
- Paper Long-term survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2015.12.024↗
- Paper Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with no… DOI 10.1002/jso.24011↗
- Paper Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. DOI 10.1038/bjc.2016.121↗
- Zev A. Wainberg · 4 shared papers, 2013–2016 · strength 0.18
- Paper Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. DOI 10.1016/j.jmoldx.2016.03.006↗
- Paper Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with no… DOI 10.1002/jso.24011↗
- Paper Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. DOI 10.1038/bjc.2016.121↗
- Jacob S. Ankeny · 4 shared papers, 2013–2016 · strength 0.18
- Paper Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. DOI 10.1016/j.jmoldx.2016.03.006↗
- Paper A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. DOI 10.1007/s11307-014-0733-4↗
- Paper Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. DOI 10.1038/bjc.2016.121↗
- David W. Dawson · 3 shared papers, 2014–2016 · strength 0.15
- Paper Long-term survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2015.12.024↗
- Paper Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with no… DOI 10.1002/jso.24011↗
- Paper Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and … DOI 10.1001/jamasurg.2013.2690↗
- Mark D. Girgis MD · 3 shared papers, 2013–2016 · strength 0.13
- Paper A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. DOI 10.1007/s11307-014-0733-4↗
- Paper Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. DOI 10.1038/bjc.2016.121↗
- Paper An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of po… DOI 10.1016/j.jss.2013.05.095↗
- Colin M. Court · 2 shared papers, 2016 · strength 0.10
- V. Raman Muthusamy · 2 shared papers, 2015–2016 · strength 0.09
- Anna M Wu · 2 shared papers, 2013–2014 · strength 0.09
- James Steven Tomlinson · 2 shared papers, 2013–2014 · strength 0.09
- William H. Isacoff · 2 shared papers, 2013–2014 · strength 0.07
- Graham W. Donald · 2 shared papers, 2013–2014 · strength 0.07
- Brian E. Kadera · 2 shared papers, 2013–2014 · strength 0.07
- Alexander P. Stark · 1 shared paper, 2016 · strength 0.06
- Guido Eibl · 1 shared paper, 2016 · strength 0.06
- Greg D. Sacks · 1 shared paper, 2016 · strength 0.06
- Andrew Hieu Nguyen · 1 shared paper, 2015 · strength 0.05
- Jennifer L. Williams · 1 shared paper, 2015 · strength 0.05
- Rabindra R. Watson · 1 shared paper, 2016 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.